INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
SEC FORM 4/Option exerciseVerified data

Meluzio Michael Vincent reported CUE

VP, Prin. Accounting Officer · Cue Biopharma, Inc. · Common Stock

Side
M
Value
—
Shares
13.6K
Price
—
Executed
Aug 13, 2026
Disclosed
Aug 17, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Aug 13 executedAug 17, 2026 disclosed

CUE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 33.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CUE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    27
    MV
    Meluzio Michael VincentVP, Prin. Accounting Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$32K
    1,144 sh
    		Oct 12, 2026Oct 14, 2026
    traded Oct 12, 2026
    		+2dSEC FORM 4

    Evidence

    27
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$30K
    1,087 sh
    		Oct 12, 2026Oct 14, 2026
    traded Oct 12, 2026
    		+2dSEC FORM 4

    Evidence

    34
    RS
    Ray SumitaChief Legal Compliance Officer, Corporate Secretary
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$52K
    1,844 sh
    		Oct 12, 2026Oct 14, 2026
    traded Oct 12, 2026
    		+2dSEC FORM 4

    Evidence

    33
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$275K
    10.0K sh
    		Oct 12, 2026Oct 14, 2026
    traded Oct 12, 2026
    		+2dSEC FORM 4

    Evidence

    21
    MV
    Meluzio Michael VincentVP, Prin. Accounting Officer
    CUECue Biopharma, Inc.
    Option exercise
    		M—
    13.6K sh
    		Aug 13, 2026Aug 17, 2026
    traded Aug 13, 2026
    		+4dSEC FORM 4

    Evidence

    26
    MV
    Meluzio Michael VincentVP, Prin. Accounting Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$45K
    1,519 sh
    		Aug 13, 2026Aug 17, 2026
    traded Aug 13, 2026
    		+4dSEC FORM 4

    Evidence

    33
    MV
    Meluzio Michael VincentVP, Prin. Accounting Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$125K
    4,106 sh
    		Aug 13, 2026Aug 17, 2026
    traded Aug 13, 2026
    		+4dSEC FORM 4

    Evidence

    26
    MV
    Meluzio Michael VincentVP, Prin. Accounting Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$93.39
    3 sh
    		Aug 13, 2026Aug 17, 2026
    traded Aug 13, 2026
    		+4dSEC FORM 4

    Evidence

    32
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$924K
    34.2K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    13
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Option exercise
    		M—
    109.2K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    29
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$160K
    5,775 sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    25
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$147K
    5,423 sh
    		Aug 13, 2026Aug 14, 2026
    traded Aug 13, 2026
    		+1dSEC FORM 4

    Evidence

    25
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$67K
    2,375 sh
    		Aug 13, 2026Aug 14, 2026
    traded Aug 13, 2026
    		+1dSEC FORM 4

    Evidence

    28
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Open-market sale
    		SELL$308K
    10.5K sh
    		Aug 13, 2026Aug 14, 2026
    traded Aug 13, 2026
    		+1dSEC FORM 4

    Evidence

    21
    LL
    Lin Shao-LeeDirector, Chief Executive Officer
    CUECue Biopharma, Inc.
    Option exercise
    		M—
    109.2K sh
    		Aug 12, 2026Aug 14, 2026
    traded Aug 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MM
    Meehan Viola MongDirector
    CUECue Biopharma, Inc.
    Grant or award
    		A—
    1,626 sh
    		May 30, 2026Jun 2, 2026
    traded May 30, 2026
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002138368-26-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 13, 2026
    Published
    Aug 17, 2026
    Ingested by INSIDER
    Nov 5, 02:22 UTC
    Last re-read
    Nov 5, 02:22 UTC

    Extracted facts

    Filer
    Meluzio Michael Vincent
    Role
    VP, Prin. Accounting Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Cue Biopharma, Inc.
    Ticker
    CUE
    Shares
    13.6K
    Price per share
    $0
    Execution date (reported)
    Aug 13, 2026
    Owned after transaction
    54.6K shares
    Days from execution to publication
    4

    What this establishes

    Meluzio Michael Vincent filed this Form 4 reporting a option exercise of CUE on Aug 13, 2026. It became public on Aug 17, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    VP, Prin. Accounting Officer
    Meluzio Michael Vincentcik:0002138368
    Issuer
    Cue Biopharma, Inc.cik:0001645460

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.